Lethal course of meconium ileus in preterm twins revealing a novel cystic fibrosis mutation (p.Cys524Tyr)
© Puzik et al.; licensee BioMed Central Ltd. 2014
Received: 11 July 2013
Accepted: 14 January 2014
Published: 17 January 2014
In term newborns meconium ileus is frequently associated with cystic fibrosis. Reports on meconium ileus in preterm infants being diagnosed with cystic fibrosis early after birth are very scarce. Associations between genotype and phenotype in cystic fibrosis and its particular comorbidities have been reported.
Two extremely preterm twin infants (26 weeks of gestation) born from a Malaysian mother and a Caucasian father were presented with typical signs of meconium ileus. Despite immediate surgery both displayed a unique and finally lethal course. Mutation analysis revealed a novel, probably pathogenic cystic fibrosis mutation, p.Cys524Tyr. The novel mutation might explain the severity of disease next to typical sequelae of prematurity.
Preterm neonates with meconium ileus have to be evaluated for cystic fibrosis beyond ethnical boundaries, but may take devastating clinical courses despite early treatment. The novel, potentially pathogenic CF mutation p.Cys524Tyr might be associated with severe meconium ileus in neonates. Disease-modifying loci are important targets for intestinal comorbidity of cystic fibrosis.
KeywordsPreterm infant Meconium ileus Cystic fibrosis Mutation Disease modifying gene locus Surgery
Reports on patients with significant prematurity, meconium ileus (MI) and cystic fibrosis (CF) are scarce to the best of our knowledge. Given the fact that ethnicity plays an important role in the occurrence of CF it is of interest to note that MI is generally rare in Malaysia, as is CF in Asia . In general, MI in neonates is thought to account for more than 80% of diagnoses of CF, although only 10-20% of CF patients develop MI [2, 3].
Gorter et al. (2010) reported that preterm infants more likely experienced MI without CF and had more complex MI (perforation, atresia, necrosis, volvulus) . The outcome after surgery was favourable, whereas outcome after intestinal perforation was associated with poor survival . Interestingly, survival does not differ between CF patients with and without MI, although MI seems to define more severe disease courses .
The role of genetic factors influencing severity and outcome of CF is less well defined. Compound heterozygosity and different modifier loci seem to have a similar impact on disease penetrance and comorbidities as the genotype itself [5–7].
We report on the unique and finally lethal course and complications of extremely preterm twins being diagnosed with a new CF mutation and review and discuss the genetic impact on CF.
Extremely preterm male twins (26 + 6/7 weeks of gestation, birth weight 980 g and 920 g, monochorionic-diamniotic, Malaysian mother, Caucasian father) were referred to us from an affiliated hospital on day 9 of life for persistent MI despite repetitive rectal irrigations.
A laparotomy on day 10 revealed MI with severe distension of the distal small intestine, microcolon and bowel adhesions. It was essential to form a Bishop-Koop stoma. After starting to pass meconium and tolerating oral feeding initially his haemoglobin level suddenly dropped on day 28 and ultrasound showed intra-abdominal effusion.
During re-laparotomy multiple hepatic haematoma and bloody ascites were apparent, besides adhesions, multiple coproliths and infarcted and perforated parts of the small intestine. Necrotic parts of the intestine were resected and the Bishop-Koop stoma was converted into two terminal enterostomies. Abdominal wall closure was achieved with a Goretex patch.
In addition, the patient developed respiratory and circulatory failure and consumption coagulopathy. Due to abdominal compartment syndrome the Goretex patch had to be removed forming a laparostoma. He finally displayed refractory metabolic acidosis leading to sudden bradycardia with cardiac arrest.
Twin II developed respiratory failure after birth necessitating mechanical ventilation and surfactant administration (Apgar score 3/7/7). Diagnostics on admission to our unit were similar compared to twin I (see Figure 1b).
Explorative laparotomy on day 11 revealed complete volvulus with partial gangrene of the ileum. Therefore, 6 cm of ileum were resected and a T drainage was placed in order to decompress the small intestine. During all of the surgical procedures he exhibited circulatory and renal failure requiring high dose vasopressors and diuretics.
When finally off the ventilator on day 37, twin II developed two spontaneous perforations next to the duodenum, which led to fistulas in the surface of the laparostoma. Without further surgical options at this time he received permanent parenteral nutrition via central venous lines, which led to three septic episodes.
Moreover, after just 6 weeks of treatment a severe hepatopathy with massive elevation of liver enzymes and bilirubin (max. 30 mg/dl, direct 19 mg/dl) became evident. At an age of 4 months liver synthesis function significantly declined necessitating daily substitution of plasma and albumin. A liver biopsy during next surgery proved 50% fibrosis.
Finally, the last option was the reconstruction of the continuity of the intestine. Unfortunately, soon after successful adhesiolysis and anastomosis of the remaining bowel 4 months after birth further spontaneous perforations occurred and we decided to stop therapy in compliance with the parents and after ethical review.
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) mutation analysis in both twins had been performed after the first surgery, initially using the Cystic Fibrosis v3Genotyping Assay (Abbott Laboratories, Wiesbaden, Germany) and subsequently by Sanger sequencing of the entire coding region (27 exons) and 50 bp of flanking intronic sequences of the gene. Mutation analysis showed compound heterozygosity for the common CFTR mutation p.Phe508del (F508del or ∆F508, c.1521_1523delCTT at the DNA level) and another, as yet unknown mutation, p.Cys524Tyr (C524Y, c.1571G > A at the DNA level), both in exon 11. Mutation analysis in the parents revealed that the father was heterozygous p.Phe508del mutation, and the mother was a heterozygous carrier of the c.1571G > A mutation, thus confirming that the mutations occurred on different alleles (in trans) in the patients. Both the PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/) and Mutation Taster software (http://neurocore.charite.de/MutationTaster/) classified the c.1571G > A mutation as protein damaging.
The impact of compound heterozygosity on disease course seems to depend on exact genotypes, as the milder mutation seems to be dominant and lead to milder courses . Compound heterozygote ∆F508 patients differ from homozygote patients in degrees of pancreas insufficiency and sweat chloride levels, but not in the incidence of MI or lung function [6, 7]. Especially the pancreas status of CF patients has been related to certain genotypes .
Nevertheless, there have been described associations of mutations like 621 + 1G- > T or G551D with the incidence of MI [6, 7]. In contrast, Zielinski et al. excluded specific MI related CF mutations, but reported a higher incidence of MI in patients with a CF modifier locus on chromosome 19q13 (CFM1 gene, encoding for a calcium-dependant chloride channel) [5, 8]. Further modifier loci (e.g. beta-defensins) have been reported and seem to be equally important in penetrance of MI and in lung function as disease defining gene mutations [5, 9].
We have found a novel CFTR mutation which has not been previously described (http://www.genet.sickkids.on.ca/cftr/) and also not been reported as a variant in the 1000 Genomes Database (http://browser.1000genomes.org/index.html). A different, nonsense, mutation affecting the same codon, c.1572C > A (p.Cys524*), has previously been described in a CF patient . Considering the position of the mutation in the region encoding the first nucleotide binding domain of the protein, it is highly likely that this mutation, together with F508del, is responsible for the CF in our patients.
In conclusion we report on two extremely preterm male twins who were compound heterozygous for a potentially pathogenic, novel CF mutation, which might explain the severity of their disease despite early treatment. Both suffered from sequelae of prematurity and early onset CF, which led to multi organ dysfunction. Preterm infants with MI have to be evaluated for CF. Neonatal screening for CF might contribute to early diagnosis and treatment. Disease modifying loci have to be considered next to genotypes when defining severity and comorbidities of CF.
Written informed consent was obtained from the parents for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Cystic fibrosis transmembrane conductance regulator
Cystic fibrosis modifier 1.
The article processing charge was funded by the German Research Foundation (DFG) and the Albert Ludwigs University Freiburg in the funding programme Open Access Publishing. Otherwise, the authors received no specific funding from any funding agency in the public, commercial, or not-for-profit sectors.
- Lim CT, Yip CH, Chang KW: Meconium ileus - a rare cause of neonatal intestinal obstruction in Malaysia. Singapore Med J. 1994, 35 (1): 74-76.PubMedGoogle Scholar
- Gorter RR, Karimi A, Sleeboom C, Kneepkens CM, Heij HA: Clinical and genetic characteristics of meconium ileus in newborns with and without cystic fibrosis. JPGN. 2010, 50: 569-572.PubMedGoogle Scholar
- van der Doef HP, Kokke FT, van der Ent CK, Houwen RH: Intestinal obstruction syndromes in cystic fibrosis: meconium ileus, Distal Intestinal Obstruction Syndrome, and constipation. Curr Gastroenterol Rep. 2011, 13: 265-270. 10.1007/s11894-011-0185-9.View ArticlePubMedPubMed CentralGoogle Scholar
- Garza-Cox S, Keeney SE, Angel CA, Thompson LL, Swischuk LE: Meconium obstruction in the very low birth weight premature infant. Pediatrics. 2004, 114 (19): 285-290.View ArticlePubMedGoogle Scholar
- Salvatore F, Scudiero O, Castaldo G: Genotype-phenotype correlation in cystic fibrosis: the role of modifier genes. Am J Med Genet. 2002, 111: 88-95. 10.1002/ajmg.10461.View ArticlePubMedGoogle Scholar
- Sebro R, Levy H, Schneck K, Dimmock D, Raby BA, Cannon CL, Broeckel U, Risch NJ: Cystic fibrosis mutations for p.F508del compound heterozygotes predict sweat chloride levels and pancreatic sufficiency. Clin Genet. 2012, 82: 546-551. 10.1111/j.1399-0004.2011.01804.x.View ArticlePubMedGoogle Scholar
- Hamosh A, Corey M: Correlation between genotype and phenotype in patients with cystic fibrosis. For the Cystic Fibrosis Genotype-Phenotype Consortium. N Engl J Med. 1993, 329 (18): 1308-1313.View ArticleGoogle Scholar
- Zielenski J, Corey M, Rozmahel R, Markiewicz D, Aznarez I, Casals T, Larriba S, Mercier B, Cutting GR, Krebsova A, Macek M, Langfelder-Schwind E, Marshall BC, DeCelie-Germana J, Claustres M, Palacio A, Bal J, Nowakowska A, Ferec C, Estivill X, Durie P, Tsui LC: Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet. 1999, 22: 128-129. 10.1038/9635.View ArticlePubMedGoogle Scholar
- Knowles M, Drumm M: The influence of genetics on cystic fibrosis phenotypes. Cold Spring Harb Perspect Med. 2012, doi:10.1101/cshperspect.a009548Google Scholar
- Jones CT, McIntosh I, Keston M, Ferguson A, Brock DJ: Three novel mutations in the cystic fibrosis gene detected by chemical cleavage: analysis of variant splicing and a nonsense mutation. Hum Mol Genet. 1992, 1 (1): 11-17. 10.1093/hmg/1.1.11.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2431/14/13/prepub
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.